IP Library Granted Patent US 10,111,956
Granted Patent B2
US 10,111,956 · App. 14/294,764 · Granted Oct 30, 2018

Corticosteroid compositions

Inventors: Robert Lathrop (Fort Collins, CO); David Wade Osborne (Fort Collins, CO)
Assignee: Tolmar, Inc.
A61K47/14A61K9/0014A61K9/06A61K9/107A61K31/56A61K31/567A61K31/573A61K31/58A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,956
App. No.
14/294,764
Granted
Oct 30, 2018
Kind
B2
Abstract

The present disclosure generally relates to pharmaceutical corticosteroid compositions, and methods of making the same.

Claims (28)

1. A pharmaceutical composition comprising:

a mixture of solvent components, comprising propylene glycol monocaprylate and propylene glycol in a ratio from 90:10 to 25:75; and

a corticosteroid selected from hydrocortisone or hydrocortisone acetate at 1.0% w/w to 5.0% w/w of the pharmaceutical composition, wherein the corticosteroid is dissolved in the solvent mixture at 1.25% w/w to 1.70% w/w of the solvent mixture;

wherein the pharmaceutical composition is a topical formulation selected from a cream, gel, and ointment.

2. The pharmaceutical composition of claim 1 , wherein the corticosteroid is at 1.25% w/w to 5.0% w/w of the pharmaceutical composition.

3. The pharmaceutical composition of claim 1 , further comprising at least one humectant selected from ethylene glycol, fructose, glycerol, lactic acid, polyethylene glycol, sorbitan, sorbitol, tetraethylene glycol, triethylene glycol, and vitamin B.

4. The pharmaceutical composition of claim 3 , wherein the humectant is lactic acid.

5. The pharmaceutical composition of claim 1 , wherein the corticosteroid is at 1.50% w/w to 5.0% w/w of the pharmaceutical composition.

6. The pharmaceutical composition of claim 1 , wherein the corticosteroid is at 1.65% w/w to 5.0% w/w of the pharmaceutical composition.

7. The pharmaceutical composition of claim 1 , wherein the corticosteroid is at 1.0% w/w to 3.0% w/w of the pharmaceutical composition.

8. The pharmaceutical composition of claim 1 , wherein the concentration of the corticosteroid dissolved in the solvent mixture is from 1.50% w/w to 1.70% w/w of the solvent mixture.

9. The pharmaceutical composition of claim 1 , wherein the concentration of the corticosteroid dissolved in the solvent mixture is from 1.65 w/w to 1.70% w/w of the solvent mixture.

10. The pharmaceutical composition of claim 1 , wherein the corticosteroid is at 2.5% w/w to 5.0 w/w of the pharmaceutical composition.

11. The pharmaceutical composition of claim 1 , wherein the corticosteroid is at 2.5% w/w to 3.0% w/w of the pharmaceutical composition.

12. The pharmaceutical composition of claim 1 , wherein the corticosteroid is at 2.5% w/w of the pharmaceutical composition.

13. The pharmaceutical composition of claim 1 , wherein the formulation is a cream comprising an oil phase, a water phase and an emulsifier.

14. The pharmaceutical composition of claim 1 , wherein the formulation is a gel comprising a gelling agent selected from the group consisting of starch, cellulose derivatives, carbomers, magnesium-aluminum silicates, xanthan gum, colloidal silica, and aluminum or zinc soaps.

15. The pharmaceutical composition of claim 1 , wherein the formulation is an ointment comprising greater than 50% by weight hydrocarbons, waxes, or polyethylene glycol.

16. A pharmaceutical composition comprising:

a mixture of solvent components, comprising propylene glycol monocaprylate, propylene glycol and ethoxydiglycol, wherein the propylene glycol monocaprylate and propylene glycol are in a ratio from 90:10 to 25:75; and

a corticosteroid selected from hydrocortisone or hydrocortisone acetate at 1.0% w/w to 5.0% w/w of the pharmaceutical composition, wherein the corticosteroid is dissolved in the solvent mixture at 1.90% w/w to 2.43% w/w of the solvent mixture;

wherein the pharmaceutical composition is a topical formulation selected from a cream, gel, and ointment.

17. The pharmaceutical composition of claim 16 , wherein the ratio of ethoxydiglycol to the total of propylene glycol monocaprylate and propylene glycol is 1:1.

18. The pharmaceutical composition of claim 16 , wherein the corticosteroid is at 2.5% w/w to 5.0% w/w of the pharmaceutical composition.

19. The pharmaceutical composition of claim 16 , wherein the corticosteroid is at 2.5% w/w to 3.0% w/w of the pharmaceutical composition.

20. The pharmaceutical composition of claim 16 , wherein the concentration of the corticosteroid dissolved in the solvent mixture is from 2.17% w/w to 2.43% w/w of the solvent mixture.

21. The pharmaceutical composition of claim 16 , wherein the concentration of the corticosteroid dissolved in the solvent mixture is from 2.33% w/w to 2.43% w/w of the solvent mixture.

22. The pharmaceutical composition of claim 16 , wherein the corticosteroid is at 2.5% w/w of the pharmaceutical composition.

Assignments (2)
SECURITY INTEREST Recorded Oct 2, 2017
From: TOLMAR THERAPEUTICS, INC.; TOLMAR, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 043756/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2014
From: LATHROP, ROBERT; OSBORNE, DAVID WADE
To: TOLMAR, INC.
Reel/Frame 033155/0897 →
Continuity (4)
Continuation PCTUS2014040560 · Jun 2, 2014
Provisional Application 61830531 · Jun 3, 2013
Related Publication 20140357607A1 · Dec 4, 2014
Related Publication 20150209429A9 · Jul 30, 2015